Minerva Neurosciences (NERV) Research & Development (2013 - 2026)

Minerva Neurosciences (NERV) has 14 years of Research & Development data on file, last reported at $5.3 million in Q1 2026.

• Quarterly Research & Development rose 285.7% year-over-year to $5.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.7 million (up 6.14% YoY) and the FY2025 annual result came in at $5.8 million, down 51.6% from the prior year.
• Research & Development improved to $5.3 million in Q1 2026, from $2.2 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $5.3 million in Q1 2026 to a low of $925377.0 in Q3 2025.
• A 5-year average of $3.0 million and a median of $2.7 million in 2023 frame the typical range for Research & Development.
• Annual changes were most pronounced in 2022 — Research & Development slumped 82.98% — and 2026, when it surged 285.7%.
• Tracing NERV's Research & Development over 5 years: stood at $3.2 million in 2022, then surged by 47.99% to $4.7 million in 2023, then tumbled by 58.0% to $2.0 million in 2024, then advanced by 9.62% to $2.2 million in 2025, then jumped by 141.76% to $5.3 million in 2026.
• The last three Research & Development figures came in at $5.3 million (Q1 2026), $2.2 million (Q4 2025), and $925377.0 (Q3 2025), per Business Quant data.